Multiple Myeloma Drugs are Getting Better with Major Pharmaceutical Companies Laying
Emphasis on R&D
Multiple myeloma is a type of cancer that forms a type of white blood cell called a plasma cell. In
multiple myeloma, cancerous plasma cells gather around the bone marrow and crowd out healthy
cells. Some of the most common symptoms of multiple myeloma are pain in the back or bones,
anemia, fatigue, and kidney damage. Multiple myelomas can be identified by a biopsy, which is
conducted when tissue samples from the affected area are taken and examined under a microscope.
When multiple myelomas are detected on an examination, it is typically very easy to remove them
with a scalpel, and in many cases, surgeons will opt to remove only one lobe of tissue at a time.
There has the development of various multiple myeloma drugs over the years with key industry
players being involved in continuous research and development activities. Selinexor is one of the
latest U.S. FDA-approved drug for multiple myeloma and is used to treat people suffering from
relapsed or refractory disease. Furthermore, Ixazomib is the first and only oral proteasome inhibitor,
indicated for multiple myeloma treatment. This drug block growth of the proteasome enzyme,
which is responsible for growth of cancer cells. It is combined with dexamethasone and
lenalidomide. Transplants are another treatment option used in multiple myeloma.